Pieter J. Schol
A5023117036- Immune Cell Function and Interaction
- Immune cells in cancer
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Genomics and Chromatin Dynamics
- Prostate Cancer Treatment and Research
- Inflammation biomarkers and pathways
- IL-33, ST2, and ILC Pathways
- Phagocytosis and Immune Regulation
- T-cell and B-cell Immunology
- interferon and immune responses
Leiden University Medical Center
2022-2024
Oncode Institute
2022-2024
Dana-Farber Cancer Institute
2022
The Netherlands Cancer Institute
2022
Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment ex vivo. Using dynamic single-cell RNA sequencing explants treated with a agonist, observed CXCR3...
Abstract Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR chromatin binding profiles are highly plastic form recurrent programmatic changes that differentiate disease stages, subtypes patient outcomes. While prior studies focused on concordance between subgroups, inter-tumor heterogeneity of enhancer selectivity remains unexplored. Here we report high levels in human primary tumors, overlap with observed healthy epithelium. Such has functional consequences,...
Human natural killer (NK) cells in lymphoid tissues can be categorized into three subsets: CD56brightCD16+, CD56dimCD16+ and CD69+CXCR6+ tissue-resident (lt)NK cells. How the subsets are functionally developmentally related is currently unknown. Therefore, we performed single-cell RNA sequencing combined with oligonucleotide-conjugated antibodies against CD56, CXCR6, CD117 CD34 on fresh bone marrow NK A minor CD56dimGzmK+ subset was identified that shared features CD56bright CD56dimGzmK-...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
<div>Abstract<p>Activation of the stimulator interferon genes (STING) pathway promotes antitumor immunity but STING agonists have yet to achieve clinical success. Increased understanding mechanism action in human tumors is key developing therapeutic combinations that activate effective innate immunity. Here, we report malignant pleural mesothelioma cells robustly express and are responsive agonist treatment <i>ex vivo</i>. Using dynamic single-cell RNA sequencing...
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Supplementary Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy